Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Catalys Pacific

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 7
Average round size
info
The average size of a deal this fund participated in
$30M
Portfolio companies 4
Rounds per year 2.33
Lead investments 1
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.43
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Pharmaceutical
  • Biopharma
  • Medical
  • Life Science

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Catalys Pacific:
There are no funds here. If we find new data, we will add it here.
Typical Co-investors
Catalys Pacific is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Catalys Pacific:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from Japan
Funds with similar focus located in Japan:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Mineralys Therapeutics

Biopharma
Biotechnology
Medical
Pharmaceutical
$118M08 Jun 2022 Radnor, Pennsylvania, United States

Aculys Pharma

Pharmaceutical
$25M28 Mar 2022 Fujisawa, Kanagawa Prefecture, Japan

Aculys Pharma

Pharmaceutical
$3M28 Oct 2021 Fujisawa, Kanagawa Prefecture, Japan

Pathalys Pharma

Biopharma
Biotechnology
$11M22 Jun 2021 Raleigh, North Carolina, United States

Mineralys Therapeutics

Biopharma
Biotechnology
Medical
Pharmaceutical
$4M06 Apr 2021 Radnor, Pennsylvania, United States

Exalys Therapeutics

Biotechnology
Life Science
Therapeutics
$15M16 Jul 2020 San Diego, California, United States
News
HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate

– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures.
– The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Catalys Pacific?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: